CAMP Antikörper

Produktnummer ABIN487626

Der Schaf Polyklonal Anti-CAMP-Antikörper wurde für EIA validiert. Er ist geeignet, CAMP in Proben von zu detektieren.

Kurzübersicht für CAMP Antikörper (ABIN487626)

Target: CAMP (cAMP) (Cyclic Adenosine Monophosphate (cAMP))

Reaktivität: Bitte anfragen

Wirt: Schaf

Klonalität: Polyklonal

Konjugat: Dieser CAMP Antikörper ist unkonjugiert

Applikation: Enzyme Immunoassay (EIA)

Produktdetails anti-CAMP Antikörper

Aufreinigung: Ig Fraction

Immunogen: Cyclic AMP-BSA

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: ELISA: 6.05 μg/mL.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 6.05mg/mL (U.V. abs at 280nm)

Buffer: 20 mM Phosphate, 150 mM Sodium Chloride, pH 7.2 containing 0.09 % Sodium Azide as preservative

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Avoid repeated freezing and thawing.

Lagerung: -20 °C

Details zu CAMP

Target: CAMP (cAMP) (Cyclic Adenosine Monophosphate (cAMP))

Andere Bezeichnung: cAMP / Cyclic AMP

Substanzklasse: Chemical

Hintergrund: Cyclic adenosine monophosphate (cAMP) plays a key role as an intracellular second messenger for transduction events that follow a number of extracellular signals. The G-Protein Coupled Receptors (GPCR) is the largest family of cell surface receptors. They can be activated by different ligands, such as neurotransmitters, hormones, ions, small molecules, peptides, and other physiological signaling molecules. Typically, the binding of the ligands to its receptor resulting in the activation of G-proteins, in return, activates the effector adenylyl cyclase evoking the production of cAMP. The activation of a protein kinase by cAMP results in the phosphorylation of substrate proteins. Currently successful drugs in marketing have been developed to target these receptors. Among the GPCRs, ~367 receptors are potential drug development targets, but only about 20 have been used to generate therapeutically and commercially successful drugs so far. Because the involvement of cAMP can amplify the response of the ligand binding, the second messenger cAMP has been largely employed to monitor the activation of the GPCR to facilitate the therapeutic drug discovery.

Pathways: Cellular Response to Molecule of Bacterial Origin